Prosecution Insights
Last updated: November 04, 2026
Application No. 19/014,484

METHODS, SYSTEMS, AND COMPUTER PROGRAM PRODUCT FOR CONFIGURING A COMPUTER READABLE MEDIUM WITH A DATA STRUCTURE INCLUDING HETEROGENEOUSLY OBTAINED DRUG PRODUCT INFORMATION

Non-Final OA §101§102§103§112
Filed
Jan 09, 2025
Priority
Jan 12, 2024 — provisional 63/620,424
Examiner
YENTRAPATI, AVINASH
Art Unit
Tech Center
Assignee
Parata Systems LLC
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
1y 1m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
527 granted / 702 resolved
+15.1% vs TC avg
Minimal -4% lift
Without
With
+-4.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
19 currently pending
Career history
731
Total Applications
across all art units

Statute-Specific Performance

§101
10.8%
-29.2% vs TC avg
§103
54.3%
+14.3% vs TC avg
§102
22.1%
-17.9% vs TC avg
§112
11.6%
-28.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 702 resolved cases

Office Action

§101 §102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-9, 12-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. Independent claims recite “processing the image of the drug product to acquire a plurality of characteristics associated with the drug product” which falls under the grouping of Mental Processes because the plain meaning of processing the OCT image encompasses mental observations or evaluation of the image to acquire characteristics or features of the image. The claims further recite “acquiring an identity of a drug product from a drug product information repository; receiving information associated with the drug product from a drug product package validation system, the information comprising an image of the drug product and the identity of the drug product” which are data gathering steps which are insignificant extra solution activities. Similarly, the limitation “configuring a non-transitory computer readable medium with a data structure that associates the identity of the drug product with the plurality of characteristics” is essentially a data output step, i.e., outputting the data to a storage device, which is an insignificant extra-solution activity. The claim does not integrate the judicial exception into a practical application because it does not recite any additional elements. Dependent claims 2 and 16 recite “wherein the plurality of characteristics comprises size, shape, color, imprint code, weight, or scoring” which is basically describing the characteristics or features of the drug product image. Dependent claims 3 and 17 recite “wherein the imprint code comprises an indicium of medicinal strength, an indicium of an active ingredient, and an indicium of an inactive ingredient” which is basically describing the characteristics or features of the drug product image. Dependent claims 4 and 18 recite “wherein the shape comprises round, elliptical, capsule, triangular, oblong, oval, square, diamond, hexagon, octagon, pentagon, gelcap, non-uniform, and other” which is basically describing the characteristics of the drug that is imaged. Dependent claims 5 and 18 recite “wherein the color comprises transparent and a plurality of colors” which is basically describing the characteristics of the drug product image. Dependent claims 6 and 19 recite “wherein the identity comprises a National Drug Code (NDC), a Drug Identification Number (DIN) identifier, or a Universal Product Code (UPC) identifier” which is basically describing the drug code information on the drug product image. Dependent claim 7 recites “wherein the drug product information repository comprises one or more commercially available databases or proprietary databases” which basically describes a database from which the information is received. Dependent claim 8 recites “determining, using an Artificial Intelligence (Al) model, the identity of the drug product based on one or more of the plurality of characteristics” but does not recite any details on how the model operates and the plain meaning of determining the identity of the drug product encompasses mental observations or evaluation of image to identify the drug. The machine learning model is recited at a high level of generality and merely confines the use of the use of an abstract idea to a particular technological environment (machine learning model) and thus fails to add an inventive concept to the claims. Claim 8 further recites “wherein receiving the information associated with the drug product from the drug product package validation system comprises receiving the information associated with the drug product from the Al model” which is merely a data gathering step which is an insignificant extra-solution activity. Dependent claim 9 recites “filtering the information based on at least one of the plurality of characteristics to identify one of the plurality of Al models” which falls under the grouping of Mental Processes because a person can mentally identify or select an AI model from a plurality of models based mentally evaluating the characteristics of the image. Claim 9 further recites “and wherein determining, using the Al model, comprises: determining, using one of the plurality of Al models, the identity of the first drug product based on the one or more of the plurality of characteristics” but does not recite any details on how the model operates and the plain meaning of determining the identity of the drug product encompasses mental observations or evaluation of image to identify the drug. The machine learning model is recited at a high level of generality and merely confines the use of the use of an abstract idea to a particular technological environment (machine learning model) and thus fails to add an inventive concept to the claims. Dependent claim 12 recite “filtering the information based on all of the plurality of characteristics to identify the one of the plurality of Al models” which falls under the grouping of Mental Processes because a person can mentally identify or select an AI model from a plurality of models based mentally evaluating the characteristics of the image. Dependent claim 13 recites “wherein each of the plurality of AI models comprises a convolutional neural network” which merely names the machine learning model but does not recite any details on how the model operates. The machine learning model is recited at a high level of generality and merely confines the use of the use of an abstract idea to a particular technological environment (machine learning model) and thus fails to add an inventive concept to the claims. Dependent claim 14 recites “wherein the convolutional neural network comprises a plurality of convolutional layers with at least some of the plurality of convolutional layers being connected to one another via a skip connection” which merely describes the kind of machine learning model but does not recite any details on how the model operates. The machine learning model is recited at a high level of generality and merely confines the use of the use of an abstract idea to a particular technological environment (machine learning model) and thus fails to add an inventive concept to the claims. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 10-11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 10 recites “wherein the plurality of artificial intelligence models corresponds to a plurality of value combinations of the one or more of the plurality of characteristics, respectively”. It is not clear what these value combinations refer to or how they are calculated. The specification does not clarify or provide details regarding the value combinations and how they correspond to the models. Claim 10 depends from claim 9 and is rejected for the same reason for failing to clarify the issue. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-2, 4-8, 15-16, 18-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by D1 (US Publication No. 2023/0098966). With regard to claim 1, D1 teach acquiring an identity of a drug product from a drug product information repository (see abstract, fig. 5, ¶¶ 45, 54: identify of the drug is acquired from database containing the training images); receiving information associated with the drug product from a drug product package validation system, the information comprising an image of the drug product and the identity of the drug product (see abstract, fig. 5, ¶¶ 45, 54: training images of drug product package with associated identify information of the drug); processing the image of the drug product to acquire a plurality of characteristics associated with the drug product (see fig. 5, ¶¶ 45, 54: image is processed to acquire features or characteristics of the drug product); and configuring a non-transitory computer readable medium with a data structure that associates the identity of the drug product with the plurality of characteristics (see fig. 5, ¶¶ 45, 54: identity of the drug is associated with plurality of characteristics such as color). With regard to claim 2, D1 teach method of claim 1, wherein the plurality of characteristics comprises size, shape, color, imprint code, weight, or scoring (see ¶ 54: color). With regard to claim 4, D1 teach method of claim 2, wherein the shape comprises round, elliptical, capsule, triangular, oblong, oval, square, diamond, hexagon, octagon, pentagon, gelcap, non-uniform, and other (see ¶ 45: characteristic information for drug products, such as capsules, pills, and the like, including size, shape, color, markings, or other identifying information). With regard to claim 5, D1 teach method of claim 2, wherein the color comprises transparent and a plurality of colors (see ¶ 54: transparency). With regard to claim 6, D1 teach method of claim 1, wherein the identity comprises a National Drug Code (NDC), a Drug Identification Number (DIN) identifier, or a Universal Product Code (UPC) identifier (see ¶ 54: identification number). With regard to claim 7, D1 teach method of claim 1, wherein the drug product information repository comprises one or more commercially available databases or proprietary databases (see fig. 1, ¶ 50: drug product databases). With regard to claim 8, D1 teach method of claim 1, further comprising: determining, using an Artificial Intelligence (Al) model, the identity of the drug product based on one or more of the plurality of characteristics (see fig. 5, ¶¶ 45 , 54: artificial intelligence to identify drug product based on one or more characteristics); wherein receiving the information associated with the drug product from the drug product package validation system comprises receiving the information associated with the drug product from the Al model (see fig. 5, ¶¶ 45, 54: package validation system receives information from the AI model). With regard to claim 15, see discussion of claim 1. D1 further teach a computer processor and memory (see fig. 1). With regard to claim 16, see discussion of claim 2. With regard to claim 18, see discussion of claims 4 and 5. With regard to claim 19, see discussion of claim 6. With regard to claim 20, see discussion of claim 1. D1 further teach a non-transitory computer readable medium (see fig. 1: computer). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 3 and 17 are rejected under 35 U.S.C. 103 as being unpatentable over D1. With regard to claim 3, D1 teach method of Claim 2, but fail to explicitly teach wherein the imprint code comprises an indicium of medicinal strength, an indicium of an active ingredient, and an indicium of an inactive ingredient. However, Examiner takes Official Notice to the fact that determining medicinal strength or active ingredients is extremely well known in the art before the effective filing date and that one skilled in the art would have been motivated to incorporate known teachings into the configuration of D1 yielding predictable results. The motivation for determining the strength or active ingredient would have been to validate the drugs before dispensing to a patient, for example. With regard to claim 17, see discussion of claim 3. Claims 9, 12-14 are rejected under 35 U.S.C. 103 as being unpatentable over D1 and further in view of D2 (US Publication No. 2024/0312173). With regard to claim 9, D1 teach method of claim 8, wherein the Al model comprises a plurality of Al models, determining, using one of the plurality of Al models, the identity of the first drug product based on the one or more of the plurality of characteristics (see fig. 5, ¶¶ 45, 54), but fails to explicitly teach filtering the information based on at least one of the plurality of characteristics to identify one of the plurality of Al models. However, D2 teach the missing feature (see ¶ 28: selecting model based on reference feature of image, e.g., if reference feature is a face, then a face model is selected). One skilled in the art would have found it obvious to combine the teachings to arrive at the claimed invention. In particular, it would have been obvious to select an AI model based on the characteristics or feature of the image which may correspond to different categories of drugs, such as drugs in a bottle or strip packaging. The teachings of D2 may be incorporated into the configuration of D1 yielding predictable results. The motivation would have been to select different AI models to recognize or classify the drugs, where different AI models may be trained on different categories of drugs, thereby enhancing recognition and classification of drugs. With regard to claim 12, D2 teach method of Claim 9, wherein filtering the information comprises: filtering the information based on see ¶ 28: selecting model based on reference feature of image, e.g., if reference feature is a face, then a face model is selected). D2 does not explicitly teach using all of the characteristics of the image to select or identify an AI model, however one skilled in the art would have found it obvious to use one or more features or characteristics of the image to filter or categorize the image into different categories and then select an AI model corresponding to the category, as explained above in claim 9. With regard to claim 13, D1 teach method of Claim 9, wherein each of the plurality of AI models comprises a see ¶ 41: AI systems may be used including, but not limited to, a multi-layer neural network, a deep learning system, a natural language processing system, and/or computer vision). D1 teach neural network but fail to explicitly teach convolution neural network, however Examiner takes Official Notice to the fact that CNN’s are extremely well known in the art before the effective filing date and one skilled in the art would have been motivated to incorporate known teachings into the configuration of D1 yielding predictable and enhanced computational efficiency and scalability. With regard to claim 14, D1 teach method of Claim 13, but fail to explicitly teach wherein the convolutional neural network comprises a plurality of convolutional layers with at least some of the plurality of convolutional layers being connected to one another via a skip connection. However, takes Official Notice to the fact that CNN’s with skip connections are extremely well known in the art before the effective filing date and one skilled in the art would have been motivated to incorporate known teachings into the configuration of D1 yielding predictable and enhanced results such as faster and more stable convergence. Pertinent Art Harrison et al. (US Publication No. 2020/0082923) is directed to capturing an image of pill bottle label and extracting features and label classification and prediction. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to AVINASH YENTRAPATI whose telephone number is (571)270-7982. The examiner can normally be reached on 8AM-5PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sumati Lefkowitz can be reached on (571) 272-3638. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AVINASH YENTRAPATI/Primary Examiner, Art Unit 2672
Read full office action

Prosecution Timeline

Jan 09, 2025
Application Filed
Oct 05, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778498
RADIOMICS SIGNATURES FOR PATHOLOGIC CHARACTERIZATION OF STRICTURES ON MR AND CT ENTEROGRAPHY
4y 0m to grant Granted Nov 03, 2026
Patent 12782826
MEASUREMENT APPARATUS, METHOD FOR OPERATING A MASK-METROLOGY MEASUREMENT APPARATUS, AND COMPUTER PROGRAM PRODUCT
2y 9m to grant Granted Nov 03, 2026
Patent 12784449
VIDEO REDACTION USING AI-BASED OBJECT DETECTION AND MOTION-BASED DETECTION
2y 7m to grant Granted Nov 03, 2026
Patent 12776005
DEVICE FOR REPLACING INTRUSIVE OBJECT IN IMAGES
2y 1m to grant Granted Oct 27, 2026
Patent 12762844
METHOD AND SYSTEM FOR GENERATING A DETECTOR FOR PROCESS MONITORING
2y 8m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
71%
With Interview (-4.2%)
2y 11m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 702 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month